The COMMENCE trial: 2-year outcomes with an aortic bioprosthesis with RESILIA tissue
JournalEuropean Journal of Cardio-thoracic Surgery
PublisherEuropean Association for Cardio-Thoracic Surgery
MetadataShow full item record
AbstractOBJECTIVES: The COMMENCE trial was conducted to evaluate the safety and effectiveness of a novel bioprosthetic tissue for surgical aortic valve replacement (AVR). METHODS: Patients underwent clinically indicated surgical AVR with the Carpentier-Edwards PERIMOUNT™ Magna Ease™ aortic valve with RESILIA™ tissue (Model 11000A) in a prospective, multinational, multicentre (n = 27), single-arm, FDA Investigational Device Exemption trial. Events were adjudicated by an independent Clinical Events Committee; echocardiograms were analysed by an independent Core Laboratory. RESULTS: Between January 2013 and February 2016, 689 patients received the study valve. Mean age was 67.0 ± 11.6 years; 71.8% were male; 26.3% were New York Heart Association Class III/IV. Mean STS PROM was 2.0 ± 1.8 (0.3–17.5). Isolated AVR was performed in 59.1% of patients; others had additional concomitant procedures, usually CABG. Thirty-day outcomes for all patients included all-cause mortality 1.2%, thromboembolism 2.2%, bleeding 0.9%, major paravalvular leak 0.1% and permanent pacemaker implantation 4.7%. Median intensive care unit and hospital length of stay were 2 (range: 0.2–66) and 7 days (3.0–121.0), respectively. At 2 years, New York Heart Association class improved in 65.7%, effective orifice area was 1.6 ± 0.5 cm2; mean gradient was 10.1 ± 4.3 mmHg; and paravalvular leak was none/trivial in 94.5%, mild in 4.9%, moderate in 0.5% and severe in 0.0%. One-year actuarial freedom from all-cause mortality for isolated AVR and for all patients was 98.2% and 97.6%, respectively. Two-year actuarial freedom from mortality in these groups was 95.3% and 94.3%, respectively. CONCLUSIONS: These data demonstrate excellent early safety and effectiveness of aortic valve replacement with a novel bioprosthetic tissue (RESILIA™). Copyright The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85046985935&doi=10.1093%2fejcts%2fezx158&partnerID=40&md5=9737a94dd400e8415673b84a987b0862; http://hdl.handle.net/10713/10016
- The sutureless aortic valve at 1 year: A large multicenter cohort study.
- Authors: Fischlein T, Meuris B, Hakim-Meibodi K, Misfeld M, Carrel T, Zembala M, Gaggianesi S, Madonna F, Laborde F, Asch F, Haverich A, CAVALIER Trial Investigators.
- Issue date: 2016 Jun
- TRANSFORM (Multicenter Experience With Rapid Deployment Edwards INTUITY Valve System for Aortic Valve Replacement) US clinical trial: Performance of a rapid deployment aortic valve.
- Authors: Barnhart GR, Accola KD, Grossi EA, Woo YJ, Mumtaz MA, Sabik JF, Slachman FN, Patel HJ, Borger MA, Garrett HE Jr, Rodriguez E, McCarthy PM, Ryan WH, Duhay FG, Mack MJ, Chitwood WR Jr, TRANSFORM Trial Investigators.
- Issue date: 2017 Feb
- Outcomes of surgical aortic valve replacement using Carpentier-Edwards PERIMOUNT bioprosthesis series in elderly patients with severe aortic valve stenosis: a retrospective cohort study.
- Authors: Nishioka N, Yamada A, Ujihira K, Iba Y, Maruyama R, Hatta E, Kurimoto Y, Nakanishi K
- Issue date: 2016 Dec
- Intermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue.
- Authors: Johnston DR, Griffith BP, Puskas JD, Bavaria JE, Svensson LG, COMMENCE Trial Investigators.
- Issue date: 2020 Feb 21
- Primary safety and effectiveness feasibility study after surgical aortic valve replacement with a new generation bioprosthesis: one-year outcomes.
- Authors: Bartuś K, Litwinowicz R, Kuśmierczyk M, Bilewska A, Bochenek M, Stąpór M, Woźniak S, Różański J, Sadowski J, Kapelak B
- Issue date: 2018